What is Epic Sciences?
Headquartered in San Diego, Epic Sciences specializes in the development of advanced diagnostic tests designed to identify and analyze circulating tumor cells (CTCs) within the bloodstream. By leveraging its proprietary platform, the company provides clinicians with a non-invasive, comprehensive view of a patient's cancer profile, facilitating more personalized and effective therapeutic interventions. The firm operates at the intersection of biotechnology and oncology, addressing the critical need for real-time monitoring of disease progression and treatment response. Its market position is bolstered by a robust portfolio of diagnostic solutions that support the entire patient journey, from initial diagnosis to long-term monitoring.
How much funding has Epic Sciences raised?
Epic Sciences has raised a total of $220.5M across 9 funding rounds:
Series C
$30M
Debt
$15M
Series D
$40M
Other Financing Round
$52M
Debt
$1M
Series F
$43M
Series G
$24M
Series C (2014): $30M supported by Domain Associates, Roche, Arcus Ventures, and Pfizer Venture Investments
Debt (2015): $15M featuring Silicon Valley Bank
Series D (2017): $40M backed by Domain Associates, Hermed Capital, Altos Capital Partners, and Genomic Health
Other Financing Round (2018): $52M with participation from Blue Ox Healthcare Partners
Debt (2020): $1M led by PPP
Series F (2022): $43M supported by Blue Ox Healthcare Partners and Arsenal Capital Partners
Series G (2023): $24M featuring Deerfield Management, Blue Ox Healthcare Partners, Arsenal Capital Partners, Labcorp, and HC Domain Ventures
Key Investors in Epic Sciences
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a track record of supporting 194 biopharmaceutical and diagnostic companies.
Blue Ox Healthcare Partners
Blue Ox Healthcare Partners is a commercial-stage growth investor focused on precision health and individualized medicine, guiding companies through the commercialization process.
Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity firm specialized in investments in middle-market industrial growth and healthcare companies, utilizing a build-for-tomorrow philosophy.
What's next for Epic Sciences?
With the successful closure of its latest funding round, Epic Sciences is well-positioned to accelerate the commercialization of its diagnostic intelligence platform. The strategic focus will likely shift toward scaling operational capacity and deepening partnerships with global pharmaceutical and diagnostic leaders. By integrating its molecular characterization capabilities into broader clinical workflows, the company aims to set new standards for precision health. Future initiatives are expected to prioritize the expansion of its test menu and the enhancement of its data analytics infrastructure, ensuring that Epic Sciences remains at the forefront of the fight against serious diseases through innovation and scientific rigor.
See full Epic Sciences company page
